Attenuated Vaccine for Human Rabies Market was valued at USD 0.10 Billion in 2022 and is projected to reach USD 0.15 Billion by 2030, growing at a CAGR of 5.4% from 2024 to 2030.
From 2018 to 2022, the market for attenuated vaccines was bolstered by several key factors. These included innovations in vaccine stability, a reduction in production costs, and increased governmental initiatives to support rabies prevention programs. With more cost-effective solutions emerging, these vaccines have become more accessible, particularly in regions where rabies is endemic. Moreover, technological advancements enabled pharmaceutical companies to develop vaccines that require fewer doses, further improving accessibility and adoption in low-income countries.
The demand for these vaccines is expected to evolve significantly from 2023 to 2033, with a continued rise in global health initiatives aimed at rabies eradication. As public health systems in both developed and developing countries continue to focus on preventing zoonotic diseases, the demand for attenuated rabies vaccines is projected to grow. Efforts from organizations such as the World Health Organization (WHO) to eliminate dog-mediated rabies by 2030 will likely drive an increased need for both preventive and post-exposure vaccines.
The coming decade will witness further growth driven by several factors, including an increase in government funding, greater collaboration between public health bodies and pharmaceutical companies, and expanded vaccination campaigns targeting high-risk populations, especially in rural and remote areas. By 2033, new vaccine formulations are likely to enter the market, with improvements in vaccine delivery methods and efficacy. This period may also see further breakthroughs in vaccine shelf life and storage, contributing to broader global distribution.
Attenuated Vaccine for Human Rabies Market
Get an In-Depth Research Analysis of the Global Attenuated Vaccine for Human Rabies Market Size And Forecast [2025-2032]
The global Attenuated Vaccine for Human Rabies Market has seen significant developments from 2018 to 2022. The increasing global awareness regarding rabies prevention, along with advancements in vaccine technology, led to an expansion in the market. Rabies remains a deadly viral disease that predominantly affects countries in Asia, Africa, and Latin America, contributing to a growing demand for human rabies vaccines. The total market outlook for this period reflected an uptick in both production and distribution, spurred by the growing recognition of the disease’s preventability. As of 2022, the market had been showing promising signs of steady growth.
AstraZeneca
GlaxoSmithKline
Merck & Co Inc
Sanofi Pasteur
Inc
Cadila Pharmaceuticals Ltd
Novartis AG
Pfizer Inc
Liaoning Yisheng Biopharmaceutical Co.
Ltd
Lanzhou Institute of Biological Products Co.
Ltd
Changchun Zhuoyi Biological Co.
Ltd
Guangzhou Nuocheng Biological Products Co.
Ltd
Ningbo Rongan Biopharmaceutical Co.
Ltd
Shandong Yidu Biotechnology Co.
Ltd
Chengdu Kanghua Biological Products Co.
Ltd
Wuhan Institute of Biological Products Co.
Ltd
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Attenuated Vaccine for Human Rabies Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Attenuated Vaccine for Human Rabies Market
Hospital
Clinic
Based on Types the Market is categorized into Below types that held the largest Attenuated Vaccine for Human Rabies market share In 2023.
Vero Cell
Human Diploid Cell
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Attenuated Vaccine for Human Rabies Market Research Analysis
1. Introduction of the Global Attenuated Vaccine for Human Rabies Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Attenuated Vaccine for Human Rabies Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Attenuated Vaccine for Human Rabies Market, By Type
6. Global Attenuated Vaccine for Human Rabies Market, By Application
7. Global Attenuated Vaccine for Human Rabies Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Attenuated Vaccine for Human Rabies Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/